U.S. Markets open in 1 hr 50 mins
  • S&P Futures

    4,407.25
    +58.25 (+1.34%)
     
  • Dow Futures

    34,517.00
    +332.00 (+0.97%)
     
  • Nasdaq Futures

    14,388.75
    +248.00 (+1.75%)
     
  • Russell 2000 Futures

    2,034.50
    +33.20 (+1.66%)
     
  • Crude Oil

    86.47
    +0.87 (+1.02%)
     
  • Gold

    1,845.40
    -7.10 (-0.38%)
     
  • Silver

    23.96
    +0.06 (+0.27%)
     
  • EUR/USD

    1.1283
    -0.0023 (-0.2031%)
     
  • 10-Yr Bond

    1.7830
    0.0000 (0.00%)
     
  • Vix

    28.62
    -0.23 (-0.80%)
     
  • GBP/USD

    1.3513
    +0.0007 (+0.0500%)
     
  • USD/JPY

    114.1910
    +0.3250 (+0.2854%)
     
  • BTC-USD

    37,909.68
    +1,392.10 (+3.81%)
     
  • CMC Crypto 200

    865.53
    +54.92 (+6.78%)
     
  • FTSE 100

    7,504.15
    +132.69 (+1.80%)
     
  • Nikkei 225

    27,011.33
    -120.01 (-0.44%)
     

Recap: Surmodics Q1 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • SRDX

 

Shares of Surmodics (NASDAQ:SRDX) rose 2.1% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share fell 60.00% over the past year to $0.02, which beat the estimate of ($0.09).

Revenue of $22,297,000 declined by 1.41% year over year, which missed the estimate of $22,370,000.

Guidance

Surmodics hasn't issued any earnings guidance for the time being.

Surmodics hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: Feb 09, 2021

View more earnings on SRDX

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/hqbfsddw

Technicals

52-week high: $49.00

Company's 52-week low was at $22.06

Price action over last quarter: Up 28.33%

Company Overview

Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The company's mission is to improve the treatment and detection of disease by using our technology to provide solutions to a difficult medical device and diagnostic challenges. It has two reportable segments: Medical device unit and Vitro diagnostics unit. Surmodics derives most of its revenue from the Medical device segment.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.